Compare IQV & KHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | KHC |
|---|---|---|
| Founded | 1982 | 1869 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 26.6B |
| IPO Year | 2013 | 2015 |
| Metric | IQV | KHC |
|---|---|---|
| Price | $156.40 | $22.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 17 |
| Target Price | ★ $227.13 | $24.50 |
| AVG Volume (30 Days) | 1.3M | ★ 11.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 7.14% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 7.84 | N/A |
| Revenue | $9,739,000,000.00 | ★ $24,942,000,000.00 |
| Revenue This Year | $6.77 | N/A |
| Revenue Next Year | $5.89 | $0.58 |
| P/E Ratio | $20.30 | ★ N/A |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $134.65 | $21.04 |
| 52 Week High | $247.05 | $29.19 |
| Indicator | IQV | KHC |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 51.48 |
| Support Level | N/A | $21.87 |
| Resistance Level | $193.26 | $24.74 |
| Average True Range (ATR) | 5.68 | 0.44 |
| MACD | -1.59 | 0.07 |
| Stochastic Oscillator | 7.16 | 65.32 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
In July 2015, Kraft merged with Heinz to create one of North America's largest food and beverage manufacturers. Beyond its namesake brands, its portfolio includes Oscar Mayer, Velveeta, and Philadelphia. While the retail channel drives around 85% of its total sales, the firm also maintains a growing foodservice presence. Outside North America, Kraft Heinz's global reach encompasses a distribution network in Europe and emerging markets, which accounts for around 25% of its consolidated sales base. The company's products are sold in more than 190 countries and territories.